I didn't call INGN a scam, but it does quack.
It may very be well that their technology has real value, but they have been consistantly spinning PR while providing minimal real data that one must suspect the worst.
It may very well be true that a semi-retrospective analysise of the existing data will indicate a good chance that a P3 trial for ADVEXIN in p53 defective patients will be a great idea. BUT, at this point it seams beyond belief that INGN will even have enough data to get a NDA accepted (none the less approved) by the FDA.
The company could come clean. The could provide more hard numbers on top line trial results (patent secrets don't cut it).
They could have come clean on the enrollment issue in T301 and the other trial, but they haen't.
How long has it been since T301 was unblinded?
Do you really believe that they haven't been able to get firgures yet (and no PR???).
Sorry, there is no chance in hell the existing data supports and NDA. The company SHOULD come clean and state :
"We now realize that ADVEXIN works only in P53 defective cancers, and the exiting trials were not designed for this. Therefore we expect the need to start another P3 trial to provide the basis for an NDA"
But they don't.
Call it spin, call it PR material for stock selling. It still quacks like a duck.
